Characterization of Determinants of Ligand Binding to the Nicotinic Acid Receptor GPR109A (HM74A/PUMA-G)

Sorin Tunaru, Jens Lättig, Jukka Kero, Gerd Krause, and Stefan Offermanns

Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany (S.T., J.K., S.O.); and Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany (J.L., G.K.)

Received June 15, 2005; accepted August 10, 2005

ABSTRACT

The G-protein-coupled receptor GPR109A (HM74A/PUMA-G) has recently been shown to function as a receptor for nicotinic acid (niacin) and to mediate its antilipolytic effects. Nicotinic acid is able to strongly raise plasma levels of high-density lipoprotein cholesterol, a property that distinguishes nicotinic acid from other lipid-lowering drugs. To investigate the structural determinants of GPR109A ligand binding, we performed site-directed mutagenesis of putative ligand binding residues combined with generation of chimeric receptors consisting of GPR109A and its close relative GPR109B, which does not bind nicotinic acid. We could identify Asn86/Trp91 (transmembrane helix (TMH) 2/extracellular loop (ECL) 1), Arg111 (TMH3), Ser178 (ECL2), Phe276 (TMH7), and Tyr284 (TMH7) as amino acid residues critical for binding of nicotinic acid. Together with data from molecular modeling studies, our data suggest that the ligand binding pocket for nicotinic acid of GPR109A is distinct from that of most other group A receptors. Although Arg111 at TMH3 serves as the basic anchor point for the carboxylate ligands, the ring system of nicotinic acid is embedded between Trp91 at the junction TMH2/ECL1 and Phe276/Tyr284 at TMH7. The heterocyclic ring is also bound to Ser178 at ECL2 via an H-bond. These data will facilitate the design of new antidyslipidemic drugs acting via GPR109A.

The water soluble B-complex vitamin nicotinic acid (niacin) has been shown to decrease plasma concentrations of total cholesterol, free fatty acids, and triglycerides when given at pharmacological doses to humans (Altschul et al., 1955; Carlson and Oro, 1962). For decades, these effects have been used to treat different dyslipidemic disorders (Olsson, 1994; Knopp, 1999). In contrast to other lipid-lowering drugs, nicotinic acid strongly raises high-density lipoprotein cholesterol levels (Blum et al., 1977; Shepherd et al., 1979). However, relatively high doses of nicotinic acid have to be administered, and the beneficial effects on lipid metabolism are accompanied by mostly harmless but disturbing side effects such as flushing, decreased glucose tolerance, or gastrointestinal effects (Olsson, 1994). Despite its long use in clinical practice, the exact mechanism of nicotinic acid-induced effects on lipid metabolism is still not completely understood. However, the inhibition of fat cell lipolysis via the activation of a G1-coupled receptor and subsequent inhibition of cAMP formation (Aktories et al., 1980, 1982) has been postulated to play an important role (Tornvall et al., 1990).

A G-protein-coupled receptor that binds nicotinic acid with the expected affinity has been identified (Soga et al., 2003; Tunaru et al., 2003; Wise et al., 2003). The receptor termed GPR109A (HM74A in human and PUMA-G in mice) is expressed in adipocytes and immune cells and couples to G-proteins of the G1 family. Activation of the receptor by nicotinic acid decreases the activity of hormone-sensitive lipase via lowering of cAMP levels, which results in a reduced hydrolysis of triglycerides to free fatty acids. In mice lacking the murine form of the nicotinic acid receptor, the antilipolytic effects of nicotinic acid, which result in a decrease in free fatty acid and triglyceride plasma levels, are abrogated (Tunaru et al., 2003). Thus, GPR109A (HM74A/PUMA-G) is the receptor mediating the antilipolytic effects of nicotinic acid. Bioinformatic data indicate that GPR109A is a member of a subfamily of G-protein-coupled receptors that comprises GPR109A (HM74A/PUMA-G) and GPR81, both of which exist in humans and in rodent species. In addition, a third member of this receptor family, GPR109B (HM74), has been found in humans, but not in mice and rats (Soga et al., 2003; Wise et al., 2003). GPR109A, GPR81, and GPR109B are

This work was supported by the Deutsche Forschungsgemeinschaft (S.O.). Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org. doi:10.1124/mol.105.015750.

ABBREVIATIONS: acifran, 4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylic acid; CHO, Chinese hamster ovary; CHAPS, 3-[3-cholamidopropyl]dimethylammonio]propanesulfonate; PBS, phosphate-buffered saline; ELISA, enzyme-linked immunosorbent assay; TMH, transmembrane helix; TM, transmembrane; ECL, extracellular loop; ELISA, enzyme-linked immunosorbent assay.
colocalized on human chromosome 12q24.31 and are most likely to be the result of gene duplications (Zellner et al., 2005). It is interesting that nicotinic acid and related compounds such as acipimox (5-methylpyrazine carboxylic acid 4-oxide) are only able to bind to GPR109A (Soga et al., 2003; Wise et al., 2003). In contrast, acifran (4,5-dihydrop-5-methyl-4-oxo-5-phenyl-2-furan carboxylic acid), which also induces changes in lipoprotein profile similar to those induced by nicotinic acid (Cayen et al., 1982; LaRosa et al., 1987) is an agonist on both GPR109A and GPR109B, indicating that GPR109B is a functional G-protein-coupled receptor (Wise et al., 2003). No ligand has been described for GPR81 so far.

Because the nicotinic acid receptor is of great interest as a target for new antidyslipidemic drugs, we have aimed in the present study to characterize the structural requirements of GPR109A for binding of nicotinic acid. Based on the high degree of homology between the human high-affinity nicotinic acid receptor GPR109A and the receptor GPR109B, which has only very low affinity for nicotinic acid, we used an iterative approach combining site-directed mutagenesis, analysis of GPR109A/GPR109B chimeras, and structural modeling to characterize the nicotinic acid-binding pocket on GPR109A.

Materials and Methods

Materials. Nicotinic acid (pyridine-3-carboxylic acid) was from Sigma (St. Louis, MO), and acifran was from Tocris Cookson Inc. (Bristol, UK).

Calcium Mobilization. CHO-K1 cells stably transfected with a calcium-sensitive bioluminescent fusion protein consisting of aequorin and green fluorescent protein (Baubet et al., 2000) were seeded in 96-well plates and were transfected with indicated cDNAs or control DNA (50 ng/well) using FuGENE6 reagent (Roche Diagnostics, Mannheim, Germany). Two days after transfection, cells were loaded with 5 μM coelenterazine h (Biotium, Hayward, CA) in calcium-free Hanks’ balanced salt solution containing 10 mM HEPES, pH 7.4, for 3.5 h at 37°C. Forty-five minutes before experiments, the buffer was replaced with Hanks’ balanced salt solution containing 1.8 mM CaCl₂. Measurements were performed by using a luminometer plate reader (Luminoskan Ascent; Thermo Electron Corporation, Waltham, MA).

Radioligand Binding. Equilibrium binding of ³H-labeled nicotinic acid (50 Ci/mmol; American Radiolabeled Chemicals, St. Louis, MO) was performed on 30 μg of membranes from human embryonic kidney 293T cells expressing wild-type or mutant receptors in a total volume of 250 μl of binding buffer [50 mM Tris-HCl, pH 7.4, 2 mM MgCl₂, and 0.02% (v/v) CHAPS] as described previously (Tunaru et al., 2003). After 4 h of incubation at 25°C, unbound and membrane-bound radioactivity were separated by filtration of the samples through nitrocellulose filters, followed by two washing steps with 4 ml of iced-cold binding buffer. Non-specific binding was determined in the presence of 200 μM unlabeled nicotinic acid.

Site-Directed Mutagenesis, Generation of Receptor Chimeras. Specific mutations introduced in GPR109A receptors were carried out based on QuikChange site-directed mutagenesis procedure (Stratagene, La Jolla, CA) using Pfu Turbo as a proofreading DNA polymerase. A receptor version carrying a FLAG-tag at the N terminus was used as a template for mutagenesis. Correct mutagenesis was confirmed by DNA sequencing. For generation of receptor chimeras, GPR109A and GPR109B receptor cDNAs were cut with BglII endonuclease. BglII has recognition sites within both receptor cDNAs that corresponds to a location between amino acids Ile139 and Ser140 of GPR109A. Additional point mutations were introduced in chimeras by site-directed mutagenesis as described above. Dimerization of Receptor Expression and Localization. CHO/G5A cells grown on glass coverslides in six-well plates were transfected with the indicated N-terminally FLAG-tagged receptors using FuGENE (Roche Diagnostics). Twenty-four hours later, cells were transferred onto ice, and the medium was removed. Cells were washed twice with ice-cold PBS and were then fixed for 30 min in 4% PFA in PBS at room temperature. To reduce the non-specific binding of the antibody, cells were blocked for 30 min in 4% fetal bovine serum in PBS at room temperature, followed by incubation for 2 h, at room temperature with anti-FLAG antibody (Sigma). After three washing steps with 2% BSA in PBS, cells were labeled with anti-mouse tetramethylrhodamine B isothiocyanate-conjugated secondary antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) for 30 min at room temperature. Cells were washed six times with Tris buffer (50 mM Tris and 150 mM NaCl, pH 7.5) and stained cells were visualized using a confocal imaging system (DM IRE2; Leica, Wetzlar, Germany).

Cell surface expression of wild-type and mutant FLAG-tagged receptors was assessed by enzyme-linked immunosorbent assay (ELISA) using Anti-FLAG antibody and horseradish peroxidase-conjugated secondary antibody (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Light generated by incubation with horseradish peroxidase substrate (Roche Diagnostics) was measured by using an Ascent Luminometer (Thermo Electron).

Homology Modeling and Ligand Docking. To generate a structural model for GPR109A/B, we adopted the X-ray structure of rhodopsin (Teller et al., 2001) from entry 1HZX of the Protein Data Bank (PDB) (Berman et al., 2000) as a template. Several receptor-specific corrections were made based on sequence alignment investigations (SeqLab, Wisconsin Package Version 10.2; Accelrys Inc. San Diego, CA). At the N-terminal tail, the two consecutive cysteines Cys18 and Cys19 are forming two additional disulfide bridges toward extracellular loop (ECL) 2 (C18-ECL2:C183) and ECL3 (C19-ECL3:C266), respectively. For transmembrane helices (TMH) 2, a structural “bulge” of Rhodopsin caused by side chain/backbone interaction of action three consecutive threonines in the rhodopsin structure would localize Asp85/Asn86 at the membrane-oriented phase of the helix. New construction of the TMH2/ECL1 junction avoids the bulge structure of rhodopsin and considers a probe kink from other TM structures (Sansom and Weinstein, 2000). The new conformation is similar to that in chemokine receptor models (proline is located on the same sequence position as in GPR109A/B). In addition, at TMH5, a minor change of orientation (10- to 15-degree twist) of the N-terminal half of TMH5 was generated as a result of different residues compared with rhodopsin before the probe kink at Pro206. The length of ECL3 was extended by an additional helix turn at TMH6 because of more residues in GPR109A/B than in the rhodopsin template. Gaps of missing residues in the intracellular loops of the template structure were closed by the “Loop Search” tool implemented in Sybyl 6.8 (Tripos Inc., St. Louis, MO) using GPR109A/B sequence. Concerning the orientation of ECL2, we started with two different models: one with the original rhodopsin fold in counter-clockwise order of residues around Cys177 and a second model with reversed, clockwise order of residues around Cys177 and a second model with reversed, clockwise order of ECL2 residues around Cys177 and a second model with reversed, clockwise order of residues around Cys177 and a second model with reversed, clockwise order of residues around Cys177. This results in a suitable geometry for pairing the additional disulfide bridges. After model generation, the structures were minimized using Amber4.1 force field and Amber95_Protein_ALL charges. In a first step, the ligands are manually docked according to the potential interaction points suggested by the results obtained with the receptor mutants. In a second step, the stability of the ligand in the binding site was studied by molecular dynamics runs in a water-vacuum-water box system (ter Laak and Kuhne, 1999) without any restraints (1.0 ns, periodic boundary box, charges neutralized by adding chlorine ions) using AMBER 7.0 (Case et al., 2002). The quality of the model and stability is validated by checking the geometry by PROCHECK (Laskowski et al., 1996) and the stability during the molecular dynamics run (overall backbone root mean square deviation, 1.7 Å).
Results

Both the human nicotinic acid receptor GPR109A and the paralogous receptor GPR109B are functional G-protein-coupled receptors that can be activated by the furan-carboxylic acid derivate acifran (Wise et al., 2003). In contrast, pyridine-3-carboxylic acid (nicotinic acid), as well as pyrazine-carboxylic acid derivatives such as acipimox, function as high-affinity agonists only on GPR109A but not on GPR109B (Soga et al., 2003; Wise et al., 2003). In addition to a shorter C terminus, GPR109A differs from GPR109B in only 17 amino acid residues that cluster around ECL1 and -2 (Fig. 1). It is likely that these amino acid residues, 14 of which are conserved in human, mouse, and rat versions of the receptor, are critically involved in ligand binding. We have therefore systematically mutated each of these amino acid residues in GPR109A into the corresponding residue of GPR109B. Nicotinic acid-induced activation of mutant receptors was tested in cells co-expressing receptor mutants and the promiscuous G-protein \( \alpha \)-subunit \( \alpha_{15} \) in a \( \mathrm{Ca}^{2+} \) reporter assay as described previously (Tunaru et al., 2003). All receptor mutants were N-terminally tagged with the FLAG epitope, and expression as well as membrane localization was verified by confocal microscopy and ELISA (see Materials and Methods). Of the 14 mutants tested, only Asn86Y, Trp91S, and Ser178I showed a severely reduced ability to respond to nicotinic acid (Fig. 2A; Table 1). All other single amino acid mutants showed unaltered or only very slightly reduced EC\(_{50}\) values for nicotinic acid-induced \( \mathrm{Ca}^{2+} \)-mobilization. The three mutants, which only weakly responded to nicotinic acid, were well expressed and showed membranous localization (Fig. 2G; Table 1). In addition, they still responded to acifran. It is noteworthy that the potency of acifran to act via these three mutants was reduced to the level observed for GPR109B (Fig. 2B; Table 1). Together, these data indicate that the mutants were functionally active. We then performed radioligand binding assays using \(^3\)H-labeled nicotinic acid (Table 1). All mutants (N86Y, W91S, and S178I) showed severely reduced binding affinities for nicotinic acid. Thus, asparagine 86, tryptophan 91, and serine 178 of GPR109A are required for high-affinity binding of nicotinic acid but are not necessary for acifran-induced receptor activation.

Because all known ligands for GPR109A carry a carboxylate group, it seemed likely that a basic residue in GPR109A is important for binding of carboxylic acid ligands. This is

![Fig. 1. Secondary structure of the human nicotinic acid receptor GPR109A.](image-url)
supported by the fact that any change or substitution at the carboxylic acid moiety of nicotinic acid, such as in nicotinamide, completely abrogates its pharmacological activity (Soga et al., 2003; Tunaru et al., 2003; Wise et al., 2003). We identified four arginine residues in TMH as candidates that may provide a binding environment for the carboxylate groups of GPR109A receptor ligands (Fig. 1). To test their potential involvement in nicotinic acid binding, we mutated arginine residues 111, 210, 251, and 253 into alanine. Although the effects of nicotinic acid and acifran on the R253A and R210A mutants were indistinguishable from those on wild-type receptor, the potencies of both agonists were re-

Fig. 2. Concentration-dependent changes in [Ca\(^{2+}\)]\(_i\) evoked in CHO-K1 cells expressing GPR109B, GPR109A, or the indicated mutants of GPR109A by nicotinic acid (A, C, and E) or acifran (B, D, and F). RLU, relative light units. Shown are mean values ± S.D. of at least three independently performed experiments. G, confocal images of CHO-K1 cells transfected with the indicated wild-type and mutant receptors. Staining was performed using an anti-FLAG antibody recognizing the N-terminal FLAG tag of the receptors.
duced when tested on the GPR109A mutant R251A. However, no receptor activation at all could be observed when nicotinic acid and acifran were tested on the GPR109A mutant R111A (Fig. 2, C and D; Table 1). Subsequent radioligand binding studies showed that the R251A mutant had a somewhat reduced affinity for nicotinic acid, whereas R111A lost its ability to bind nicotinic acid (Table 1). The R111A mutant was normally expressed and localized to the plasma membrane as shown by confocal microscopy and ELISA (Table 1, Fig. 2G). This suggests that arginine 111, which is localized in TMH3 of GPR109A and GPR109B, is crucial for ligand-dependent receptor activation by contributing to the binding pocket of the receptor. The corresponding position 3.33 (Ballesteros and Weinstein, 1992) in many GPCRs has been shown to be involved in ligand binding (Gether, 2000).

As is typical for class A G-protein-coupled receptors, GPR109A has a cysteine residue at the extracellular end of TMH3 (C3.25) that forms a disulfide bond with a cysteine residue in the ECL2. Removal of the disulfide bond by mutation of GPCRs (Savarese et al., 1992; Noda et al., 1994). GPR109A has two cysteine residues, Cys177 and Cys183, in TMH3 (C3.25) that forms a disulfide bond with a cysteine residue in the ECL2. The reduced potency of nicotinic acid at the C183A mutant of GPR109A can be explained by an additional disulfide bond established between ECL2 and one of the cysteines at the N-terminal tail, which may stabilize the conformation of ECL2.

The three residues that are different in GPR109A and GPR109B that were found to be essential for binding of nicotinic acid to GPR109A are either at the junction of TMH2 and the first ECL (Asn86 and Trp91) or in the second ECL (Ser178). This suggests that both junction TMH2/ECL1 and ECL2 are part of the binding site for nicotinic acid in GPR109A. To gain further insight into the structural requirements of GPR109A for binding of nicotinic acid, we generated chimeras of GPR109A and GPR109B. The chimeras were constructed such that the first three TM regions, including the junction TMH2/ECL1, were from one receptor, whereas the C-terminal four TM regions, including the second ECL, were from the corresponding homologous receptor (see Materials and Methods; Fig. 3A). The unselective agonist acifran was still able to activate both chimeras, although the potency of acifran toward the GPR109B/GPR109A chimera was somewhat reduced (Fig. 3, B and D). In contrast, both receptor chimeras were completely unresponsive to nicotinic acid (Fig. 3, B and C). Radioligand binding assays showed that none of the chimeras bound nicotinic acid (Fig. 3B). To further characterize the involvement of the junction TMH2/ECL1 and of ECL2 in binding of the receptor to nicotinic acid, we mutagenized the GPR109A-specific extracellular residues required for nicotinic acid binding (Asn86, Trp91, and Ser178) into the GPR109B portion of wild-type and GPR109A receptor mutants were determined by ELISA assay in nonpermeabilized CHO-K1 cells (see Materials and Methods).

### TABLE 1

Nicotinic acid and acifran evoked Ca\(^{2+}\) responses (EC\(_{50}\)) and nicotinic acid binding affinity (K\(_d\)) for GPR109A mutants

<table>
<thead>
<tr>
<th>Nicotinic Acid</th>
<th>Acifran</th>
<th>EC(_{50})</th>
<th>[(^3)H]Nicotinic Acid Binding</th>
<th>Surface Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(\mu M)</td>
<td></td>
<td>(K_d) (\text{pmol/mg})</td>
<td>RLU</td>
</tr>
<tr>
<td><strong>WT receptors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GPR109A</td>
<td>0.7 ± 0.2</td>
<td>1.9 ± 0.4</td>
<td>60 ± 8</td>
<td>3.36 ± 0.45</td>
</tr>
<tr>
<td>Inactive</td>
<td>90 ± 12</td>
<td>&gt;500</td>
<td>42.4 ± 5.99</td>
<td></td>
</tr>
<tr>
<td><strong>GPR109A mutants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L83V</td>
<td>3 ± 0.5</td>
<td>2 ± 0.3</td>
<td>&gt;500</td>
<td>45.27 ± 1.91</td>
</tr>
<tr>
<td>N86Y</td>
<td>&gt;100</td>
<td>88 ± 20</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>W91S</td>
<td>&gt;100</td>
<td>96.4 ± 10</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>K94N</td>
<td>1.4 ± 0.8</td>
<td>4 ± 0.7</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>M103V</td>
<td>5.3 ± 1.1</td>
<td>2.2 ± 0.5</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>L107F</td>
<td>3.1 ± 0.5</td>
<td>2.9 ± 0.3</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>R142W</td>
<td>1 ± 0.3</td>
<td>4.3 ± 0.5</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>I156V</td>
<td>0.5 ± 0.1</td>
<td>2.8 ± 0.4</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>M167L</td>
<td>2.3 ± 0.3</td>
<td>5.6 ± 0.2</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>P168L</td>
<td>2.3 ± 0.4</td>
<td>4.7 ± 0.6</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>G173P</td>
<td>1.1 ± 0.2</td>
<td>2.4 ± 0.3</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>L176V</td>
<td>3 ± 0.4</td>
<td>18.7 ± 2</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>S178I</td>
<td>&gt;100</td>
<td>93.1 ± 15</td>
<td>&gt;500</td>
<td>49 ± 2.8</td>
</tr>
<tr>
<td>P189L</td>
<td>0.7 ± 0.1</td>
<td>2 ± 0.1</td>
<td>&gt;500</td>
<td>39.27 ± 3.01</td>
</tr>
<tr>
<td>R111A</td>
<td>Inactive</td>
<td>Inactive</td>
<td>&gt;500</td>
<td>39.27 ± 3.01</td>
</tr>
<tr>
<td>R210A</td>
<td>0.8 ± 0.2</td>
<td>6 ± 1.5</td>
<td>&gt;500</td>
<td>40.2 ± 3.4</td>
</tr>
<tr>
<td>R251A</td>
<td>70 ± 12</td>
<td>80 ± 14</td>
<td>351 ± 22</td>
<td>4.1 ± 0.21</td>
</tr>
<tr>
<td>R253A</td>
<td>0.9 ± 0.1</td>
<td>1.9 ± 0.4</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>C100A</td>
<td>Low expression</td>
<td>Low expression</td>
<td>Low expression</td>
<td>Low expression</td>
</tr>
<tr>
<td>C177A</td>
<td>Low expression</td>
<td>Low expression</td>
<td>Low expression</td>
<td>Low expression</td>
</tr>
<tr>
<td>C183A</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;500</td>
<td>51.24 ± 4.9</td>
</tr>
<tr>
<td>C266A</td>
<td>20 ± 3</td>
<td>40 ± 9</td>
<td>160 ± 13</td>
<td>3.03 ± 0.25</td>
</tr>
</tbody>
</table>
of the GPR109A/GPR109B chimeras (see Fig. 3A). The GPR109B(Y86N,S91W)/GPR109A chimera was then again able to bind and respond to nicotinic acid. Likewise, the GPR109A/GPR109B(I178S) chimera gained responsiveness and binding toward nicotinic acid (Fig. 3A, B and C). $B_{\text{max}}$ values were 3.98 ± 0.34 pmol/mg for GPR109B(Y86N,S91W)/GPR109A and 4.01 ± 0.23 pmol/mg for GPR109A/GPR109B(I178S). All mutants were normally expressed (Fig. 2G; data not shown). These data clearly support the notion that Asn86, Trp91, and Ser178 in the junction of TMH2/ECL1 and in ECL2 of GPR109A are critically involved in nicotinic acid binding.

Our modified homology model of GPR109A, including the reversed order of ECL2, was most consistent with the experimental data, where the residues Asn86, Trp91, and Ser178 are located in close spatial proximity between the junction TMH2/ECL1 and ECL2. The mutation-sensitive basic side chain Arg111 (TMH3) is located in the interior center of the traditional binding area for the majority of G-protein-coupled receptor ligands. Docking studies, by anchoring the acidic group of nicotinic acid toward the most sensitive basic residue (Arg111 at TMH3 in the center of the receptor), allows us to define two potential binding areas for the very small ligand. In binding site I, the pyridine ring of nicotinic acid is embedded between the aromatic rings of Trp91 (junction TMH2/ECL1), Phe276 (TMH7), and Tyr284 (TMH7), whereas the ring nitrogen is simultaneously bound to Ser178 at ECL2 via an H-bond. The suitable side chain orientation of the two aromatic side chains Trp91 and Phe276 are, in the case of Trp91 (TMH2/ECL1), restrained by Asn86 (TMH2) via H-bond and, in the case of Phe276 (TMH7), restrained by Phe180 (ECL2) via aromatic interactions (Fig. 4, A and B). Binding site II would be localized at the interior receptor cleft between TMH3, TMH6, and TMH5 at the extracellular half of the transmembrane region, a common ligand binding region for the majority of small ligands such as the biogenic amine receptors of class A GPCRs. The locations of nearly all sensitive mutants for binding nicotinic acid (Table 1) are spatially distributed at site I (Arg111, Asn86, Trp91, Ser178) of the GPR109A model. The mutation of Arg251 that is localized at site II had only a weak effect on ligand binding, and ligand-induced signaling might be based on an indirect effect. (Table 1; Fig. 2).

From analyses of crystal structures of nicotinic acid bound at diverse prokaryotic proteins [such as nicotinate mononucleotide dimethylbenzimidazole phosphoribosyltransferase (PDB code 1D0V) (Cheong et al., 1999), dihydropteridine reductase (PDB code 1ICR) (Lovering et al., 2001), nicotinate nucleotide dimethylbenzimidazole phosphoribosyltransferase (PDB code 1JHA) (Cheong et al., 2001), dihydrodipicolinate reductase (PDB code 1DRV) (Reddy et al., 1996), and the plant protein ferric soybean leghemoglobin (PDB code 1FSL) (Ellis et al., 1997)], it is evident that the pyridine ring system of the ligand is always bound near aromatic side chains of the protein. Following the structural homology paradigm, we assumed that the binding pocket of GPR109A is also coated by aromatic side chain(s) as an additional binding partner for nicotinic acid. According to our ligand/receptor interaction

![Fig. 3. A, structure of the chimeric GPR109B/GPR109A receptors. Black indicates sequences and residues from GPR109A; gray indicates sequences from GPR109B. B, nicotinic acid- and acifran-evoked Ca\textsuperscript{2+} responses (EC\textsubscript{50}) and nicotinic acid binding $K_d$ for chimeric GPR109A and GPR109B receptors. Effect of increasing concentrations of nicotinic acid (C) or acifran (D) on the free intracellular Ca\textsuperscript{2+}-concentration in CHO-K1 cells expressing the promiscuous $\alpha$-protein $G_{\alpha,15}$ together with GPR109B, GPR109A, or the indicated chimeric receptors. Shown are mean values ± S.D. of at least three independently performed experiments.](image-url)
model, in addition to Trp91, Phe276 (TMH7) and Tyr284 (TMH7) were also predicted to be direct interaction partners. Residue Phe180 (ECL2) was predicted to be an indirect aromatic interaction partner at binding site I (Fig. 4B), whereas residue Phe193 (TMH5) would be a possible partner at a potential binding site II. To study whether the aromatic residues are required for ligand induced signaling and to distinguish between binding sites I and II, leucine and alanine mutants of these aromatic residues were generated. Indeed, mutation of the aromatic residues Phe276 (TMH7) and Tyr284 (TMH7) at binding site I to alanine or leucine had the strongest effects on binding of nicotinic acid and

![Interaction model of nicotinic acid (orange) at the binding site (green residues) of GPR109A receptor. Stable conformation after a 1.0-ns molecular dynamics run. A, the binding site of nicotinic acid is located between TMH2, -3, and -7 (pink/yellow ribbon). Our data do not support an alternative binding site between TMH3, -4, -5, and -6 (e.g., magenta residue F193). B, close-up view of the binding site. Acidic group of nicotinic acid (orange) interacts with the basic anchor point Arg111 at TMH3, whereas the pyridine ring is embedded between Trp91 at the junction TMH2/ECL1, Phe276, and Tyr284 at TMH7. The pyridine nitrogen is also bound to Ser178 at ECL2 via an H-bond. Asn86 (TMH2) restrains the orientation of Trp91 by hydrogen bond, and Phe180 (ECL2) restrains the orientation of Phe276 by aromatic interactions leading to a suitable and rigid binding cleft.](image-url)
acifran, indicating a direct effect on the ligand binding site (Table 2) via aromatic interactions. The alanine mutants of Phe180 and Phe193 had the same phenotypes, whereas F180L and F193L mutants were only slightly affected in their ability to bind ligand. This indicates indirect effects of alanine mutants on the ligand binding site and provides additional support for binding site I, because F193, at TMH5, is far from binding site I and would be the only residue located at a hypothetical binding site II (Fig. 4A). All mutants have expression levels similar to wild type (data not shown). The suggested additional mutations of aromatic residues further support the binding site I and confirmed the direct and indirect effects of aromatic residues at binding site I derived from the structural model.

Taken together, an iterative approach combining site-directed mutagenesis and comparative modeling of the binding pocket of nicotinic acid at GPR109A identified five residues as main interaction points. The binding pocket is located between the basic anchor site at TMH3 (Arg111) for the acidic group of the ligand and the interaction site for the ring system of the ligands formed by the junction TMH2/ECL1 (Asn86, Trp91), TMH7 (Phe276, Tyr284), and the tip of ECL2 (Ser178).

Discussion
Based on the remarkable clinical effects of nicotinic acid, its recently discovered G-protein-coupled receptor represents one of the prime targets for the development of new antidysepsilipidemic drugs (Pike and Wise, 2004). Major aims of new drug development in this field are, for example, the improvement of the relatively low potency and unfavourable pharmacokinetic properties of nicotinic acid. In addition, a better ratio of wanted and unwanted effects would be desirable. To understand more about the structural requirements for binding of ligands to the nicotinic acid receptor, we have characterized the binding site on the human nicotinic acid receptor GPR109A. We were surprised to find that our data indicate that the binding site of GPR109A for its known pharmacological small molecule ligands differs from the traditional binding site of class A G-protein-coupled receptors. The common feature of such ligands is a carboxylic group, such as in nicotinamide, completely abrogates its pharmacological activity. Based on the assumption that the carboxylic acid group forms a salt bridge with a residue in one of the TM regions of the receptors, we searched for positively charged residues that would allow for an electrostatic interaction with the carboxyl oxygens. Of four candidate arginine residues in TMH3, 6, and 7, only arginine 111 in TMH3 was absolutely required for binding of nicotinic acid to GPR109A. In contrast, mutational deletion of positively charged residues in TMH6 and -7 did not interfere with the ability of the receptor to bind nicotinic acid. It is noteworthy that the recently discovered dicarboxylic acid receptor GP91 has been suggested to require positively charged amino acid residues in TMH 6 and 7; two residues in TMH3 (He et al., 2004) and an arginine residue in TMH7 of prostanooid receptors have been suggested to bind to the C1-carboxylate of prostanooids (Stitham et al., 2003).

Class A GPCRs for small molecule agonists bind their specific ligands via the extracellular half of their 7 TM domain. Multiple mutagenesis experiments and molecular modeling structures clearly indicate that the binding sites for most small molecule agonists, such as biogenic amines, are located between TMH3, 4, 5, 6, and 7 (Strader et al., 1994; Ji et al., 1998; Bonini et al., 2000; Shi and Javitch, 2002; Stenkamp et al., 2002; Kristiansen, 2004). Our findings support a structural model for GPR109A in which the nicotinic acid binding pocket is localized between TMH2, -3, and -7.

The ligands of various receptors, such as the C3a receptor (Kim et al., 1999), the Ca$\text{++}$-sensing receptor (Miedlich et al., 2004), the prostacyclin receptor (Stitham et al., 2003), or the vasopressin V$\text{2}$ receptor (Wuller et al., 2004), are also interacting with a similar binding site on their respective receptors.

### Table 2
Nicotinic acid and acifran evoked Ca$\text{++}$ responses (EC$_{50}$) and nicotinic acid binding affinity (K$_{d}$) for aromatic residue mutants of GPR109A

<table>
<thead>
<tr>
<th>GPR109A Mutants</th>
<th>Nicotinic Acid EC$_{50}$</th>
<th>Acifran EC$_{50}$</th>
<th>[H] Nicotinic Acid Binding</th>
<th>Surface Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$\mu$M</td>
<td></td>
<td>$K_{d}$</td>
<td>$B_{max}$</td>
</tr>
<tr>
<td>F180A</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;500</td>
<td>40.78 ± 2.5</td>
</tr>
<tr>
<td>F180L</td>
<td>1.8 ± 0.2</td>
<td>5.4 ± 6</td>
<td>&gt;500</td>
<td>42.2 ± 3.9</td>
</tr>
<tr>
<td>F193A</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;500</td>
<td>39.76 ± 4.1</td>
</tr>
<tr>
<td>F193L</td>
<td>4 ± 0.6</td>
<td>8 ± 2</td>
<td>&gt;500</td>
<td>39.76 ± 4.1</td>
</tr>
<tr>
<td>F276A</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;500</td>
<td>39.76 ± 4.1</td>
</tr>
<tr>
<td>F276L</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;500</td>
<td>39.76 ± 4.1</td>
</tr>
<tr>
<td>Y284A</td>
<td>81 ± 17</td>
<td>&gt;100</td>
<td>300 ± 36</td>
<td>39.91 ± 3.7</td>
</tr>
<tr>
<td>Y284L</td>
<td>153 ± 10</td>
<td>&gt;100</td>
<td>342 ± 40</td>
<td>39.08 ± 4.5</td>
</tr>
</tbody>
</table>

Shown are data for the indicated GPR109A mutants. The EC$_{50}$ values of nicotinic acid-induced increases in [Ca$\text{++}$]$_{i}$ were determined in CHO-K1 cells expressing G$_{515}$ and the indicated wild-type or mutant receptors. The $K_{d}$ and $B_{max}$ values were determined by Scatchard analysis of [H]nicotinic acid binding saturation isotherms and represent the mean ± S.D. of at least three independent experiments. Relative cell surface expression levels of wild-type and GPR109A receptor mutants were determined by ELISA assay in nonpermeabilized CHO-K1 cells (see Materials and Methods).
Although the major binding sites for small molecule ligands of GPCRs are localized in the TM helices, there is evidence from site-directed mutagenesis experiments that certain residues in ECL2 can also particularly contribute to binding of small ligands to GPCRs (Kim et al., 1996; Zhao et al., 1996; Shi and Javitch, 2004). Similar to many other GPCRs, GPR109A as well has a disulfide bond between ECL2 (C177) and TMH3 (C100). Because of the disulfide linkage, ECL2 is constrained over the ligand binding pocket, and residues from ECL2 can take part in ligand binding. In our model, Ser178 of ECL2 reaches into the ligand binding pocket and interacts with the nitrogen of the pyridine ring of nicotinic acid.

As already reported for other GPCRs (Balmforth et al., 1997; Groblewski et al., 1997), in our homology model of GPR109A, the inactive state is also restrained by side-chain interactions between TMH3 and TMH6/TMH7, where Arg111 (TMH3) is very likely to be involved in side-chain interactions with Ser247 (TMH6) and Thr283 (TMH7), stabilizing/constraining the inactive conformation. Arginine 111 at TMH3 is the pivotal residue for electrostatic recognition and binding, and it functions as a basic anchor point for the acidic group of the ligands. Our findings support a scenario in which the arginine side chain is forced to delocalize from its inactive state orientation. The positively charged guanidine group of the arginine side chain moves toward the negatively charged acid group of the ligand upon binding, and the interaction between helices TMH3 and TMH6/TMH7 is weakened or lost.

According to several X-ray structures of nicotinic acid/ protein complexes, in which nicotinic acid is surrounded by aromatic residues (Reddy et al., 1996; Ellis et al., 1997; Cheong et al., 1999, 2001; Lovering et al., 2001), and based on our docking model of nicotinic acid/GPR109A, the participation of aromatic residues as direct and indirect partners in the binding site was predicted. To distinguish between direct and indirect aromatic interaction partners of the ligand, we introduced strong (alanine) and weak (leucine) alterations of side-chain properties by mutations. Mutants of Phe276 and Tyr284 showed identical strong effects for alanine and leucine as well, indicating a direct aromatic interaction of both positions on ligand binding. Whereas the common differences between alanine and leucine mutants for Phe180 and Phe193 indicate rather indirect effects of the two residues on ligand binding. Leucine mutants are preserving the necessary hydrophobic properties needed for proper orientation of the neighboring side chains. The strong side chain reduction in size and hydrophobicity in case of alanine mutants may lead to slightly altered assembly of the neighboring side chains and/or helices and thus may indirectly affect the proper shape and size of the ligand binding site. Finally, all residues experimentally identified as essential direct interaction partners are located in the GPR109A model in very close spatial proximity and provide support that the binding site of nicotinic acid is located between TMH3, junction TMH2/ECL1, TMH7, and the tip of ECL2. The data combined with the model suggest also the possibility that some aromatic residues, such as Trp91 and Phe276, play a role in the formation of a gateway that allows nicotinic acid to access the binding pocket.

Taking advantage of the high degree of sequence homology between the human high-affinity nicotinic acid receptor GPR109A and the receptor GPR109B, which has only very low affinity for nicotinic acid, we have identified critical residues for the binding of nicotinic acid to GPR109A. By combining mutagenesis data and comparative structural modeling, we were able to identify five residues located in close spatial proximity as the main interaction points for nicotinic acid. The characterization of the structural determinants and complementary pharmacophoric patterns for binding of nicotinic acid at GPR109A is of general importance for understanding the binding mechanism of small molecule ligands to GPCRs as well as for the design and development of new drugs acting via GPR109A to treat dyslipidemic disorders.

Acknowledgments

We thank R. LeFaucheur for help with the manuscript.

References


Kristiansen K (2004) Molecular mechanisms of ligand binding, signaling and regu-

double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients. *Artery* 14:338–350.

AQUA and PROCHECK-NMR: programs for checking the quality of protein struc-
tures solved by NMR. *J Biomol NMR* 8:477–486.


Olsson AG (1994) Nicotinic acid and derivatives, in *Principles and Treatment of
Lipoprotein Disorders* (Schettler G and Habenicht AJR eds) pp 349–400, Hand-

Pike NB and Wise A (2004) Identification of a nicotinic acid receptor: is this the
molecular target for the oldest lipid-lowering drug? *Curr Opin Invest Drugs*

substrates with Escherichia coli dihydrodipicolinate reductase: thermodynamic

Sansom MS and Weinstein H (2000) Hinges, swivels and switches: the role of
prolines in signalling via transmembrane alpha-helices. *Trends Pharmacol Sci*

Savarese TM, Wang CD, and Fraser CM (1992) Site-directed mutagenesis of the rat
m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor

Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, and Taunton OD (1979) Effects of
nicotinic acid therapy on plasma high density lipoprotein subfraction distribution

Shi L and Javitch JA (2002) The binding site of aminergic G protein-coupled recep-
tors: the transmembrane segments and second extracellular loop. *Annu Rev Phar-

Shi L and Javitch JA (2004) The second extracellular loop of the dopamine D2

Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohashi T, Hiyama H,

structure of rhodopsin: a template for cone visual pigments and other G protein-

ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagen-

double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipo-

in determination of a high-resolution three-dimensional structure of rhodopsin, a

ter Laak AM and Rühne R (1999) Bacteriorhodopsin in a periodic boundary water-
vacuum-water box as an example towards stable molecular dynamics simulations

residues involved in n1-adrenergic receptor subtype-selective antagonist binding.
*Biochem Biophys Res Commun* 228:118–127.

Address correspondence to: Stefan Offermanns, Institute of Pharmacology,
University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Ger-
many. E-mail: stefan.offermanns@urz.uni-heidelberg.de